apg-2449
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 27, 2019 (NCT03917043)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Focal adhesion kinase 1INHIBITOR
PTK2 inhibitor
- ALK tyrosine kinase receptorINHIBITOR
ALK inhibitor
ROS1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1=CCN(C2CCOCC2)CC1- Mol. weight
- 640.25 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095166 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06687070 | Phase 1 | Nov 30, 2024 | Ascentage Pharma Group Inc., Sun Yat-Sen University |
| NCT03917043 | Phase 1 | May 27, 2019 | Ascentage Pharma Group Inc., Sun Yat-Sen University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ascentage Pharma Group Inc. | For profit | 2 | 2 | 1 | 2019 |
| Sun Yat-Sen University | Academic/Hospital | 2 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1